What is the synthesis patent for berotralstat?
The synthesis patent for berotralstat, developed by BioCryst Pharmaceuticals, relates to the chemical process used to manufacture the drug. This patent is crucial for protecting BioCryst's investment in the drug's development and ensuring its market exclusivity for a period of time. Specific details regarding the synthesis process are proprietary and typically protected by patents filed with regulatory bodies like the U.S. Patent and Trademark Office (USPTO).
When does the berotralstat synthesis patent expire?
Patent expiration dates are critical for understanding when generic versions of a drug might become available. For berotralstat, the U.S. patent landscape can be complex, often involving multiple patents covering different aspects of the drug, including its synthesis, formulation, and methods of use. Information on specific patent expiry dates can be found on specialized databases. According to DrugPatentWatch.com, the earliest U.S. patent for berotralstat expires in 2037 [1]. This date typically marks the end of the patent protection for the initial synthesis process.
How does berotralstat work?
Berotralstat is a plasma kallikrein inhibitor used for the prophylactic treatment of hereditary angioedema (HAE) [2]. Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body [3]. By inhibiting plasma kallikrein, berotralstat helps to prevent the overproduction of bradykinin, a substance that plays a key role in the swelling associated with HAE attacks [2].
What is the difference between berotralstat and other HAE treatments?
Berotralstat is an orally administered, once-daily therapy, distinguishing it from some other HAE treatments that may require injection or infusion [2]. While other HAE therapies also aim to manage swelling attacks, they may target different pathways or have different administration routes and dosing schedules. For instance, some treatments focus on replacing or augmenting C1 esterase inhibitor, while others are monoclonal antibodies targeting different components of the inflammatory cascade [3].
Who manufactures berotralstat?
BioCryst Pharmaceuticals is the company that developed and manufactures berotralstat [2].
What are the risks associated with berotralstat?
The most common side effects of berotralstat include upper respiratory tract infection, headache, and diarrhea [2]. Patients and healthcare providers should discuss potential risks and benefits before initiating treatment.
Where can I find more information on berotralstat patents?
For detailed information on berotralstat patents, including expiration dates and any ongoing litigation or challenges, resources like DrugPatentWatch.com provide comprehensive data [1]. These platforms track patent information for numerous drugs, offering insights into patent portfolios and potential market entry for generic competitors.
Sources
[1] DrugPatentWatch.com. (n.d.). Berotralstat. https://drugpatentwatch.com/drugs/berotralstat
[2] BioCryst Pharmaceuticals. (n.d.). ORLADEYO (berotralstat) therapy. Retrieved from https://www.biocryst.com/our-products/orladeyo/
[3] National Institute of Allergy and Infectious Diseases. (2021, August 31). Hereditary Angioedema. https://www.niaid.nih.gov/diseases-conditions/hereditary-angioedema